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Abstract
 .  .The aim of this study was to investigate the effects of high density lipoprotein 3 HDL and ascorbic acid AsA in3
 .combination on copper-catalyzed low density lipoprotein LDL peroxidation. LDL and HDL were isolated from sera of3
 .healthy volunteers. LDL protein, 200 mgrml, was incubated in phosphate-buffered saline PBS containing 2.5 mM CuSO4
in the absence or presence of AsA, with HDL protein alone, or with coincubation of HDL , 200 mgrml, and AsA, 203 3
mgrml, at 378C for up to 24 h. As a control, the same amount of control LDL protein was added to PBS. The protective
 .effects of the HDL and AsA were examined by both electrophoresis and determination of the lipid hydroperoxide LPO3
level in each sample. The concentration of AsA was also measured in samples containing AsA. The coincubation of HDL 3
and AsA exerts more powerful anti-peroxidative effects against copper-catalyzed LDL peroxidation, than either of these
agents alone. In addition, AsA was retained in the media by the addition of HDL . The findings suggest that there are3
strong synergistic anti-peroxidative effects of HDL and AsA and these two may act in concert in vivo to inhibit LDL3
peroxidation and thus exert an anti-atherosclerotic effect. q 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
High concentrations of serum low density lipopro-
 .tein LDL cholesterol are directly related to the
likelihood of developing atherosclerosis. One current
theory to explain the development of the foam cell-
laden fatty streaks in the arterial wall, which is
believed to initiate atherosclerosis, proposes that the
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w xperoxidative modification of LDL is critical 1 . It has
been demonstrated that LDL, via a free-radical medi-
ated process, can be peroxidatively modified by cells
which are present in the artery wall or transition
w xmetals 2,3 . Data have accrued suggesting that per-
 .oxidized LDL ox-LDL may promote atherogenesis.
The ox-LDL is taken up by the scavenger receptor of
macrophages and this uptake facilitates foam cell
w xformation 4,5 . The ox-LDL is cytotoxic, e.g., to
endothelium, and accelerates the recruitment of
monocytes into the intima by its chemo-attractant
activity, and retention of macrophage in the arterial
w xwall 6,7 . Further evidence has been presented for
the occurrence of a modified form of LDL with many
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physical, chemical and biological properties of ox-
w xLDL in the arterial lesions 1 . Hence, anti-oxidants
have recently become a focus for preventing the
progression of atherosclerosis because of their ability
to inhibit the peroxidation of LDL. Ascorbic acid
 .AsA performs an anti-oxidative function in vivo by
serving as a hydrogen ion donor at various metabolic
sites. AsA is also a free radical scavenger, with the
highest anti-oxidative activity among the various
w xanti-oxidants found in blood plasma 8,9 , and is
thought to function in the initial protective system
w xstimulated by peroxidative stress 10 . AsA defi-
ciency induced in guinea pigs which are unable to
produce AsA in vivo leads to serious injury to en-
dothelial cells, and fatty streaks characterized by
w xfoam cells 11,12 . When AsA deficiency is induced
in osteogenic disorder Shionogi rats that are geneti-
cally incapable of producing AsA, increased serum
lipid-peroxide and aortic endothelial cell injury are
w xalso observed 13 . The levels of AsA in leukocytes
in patients with coronary heart disease are lower than
w xthose in subjects without coronary artery disease 14 .
Another study demonstrated that low aortic AsA
concentrations exist in cases of human abdominal
aneurysmal and occlusive disease as compared to
w xsubjects without diseased aorta 15 . Clinical, epi-
demiological, and experimental findings thus strongly
indicate that low AsA levels in humans promote the
formation of atherosclerosis. We have previously re-
ported that AsA inhibits the production of ox-LDL in
w xvitro in a concentration-dependent manner 16 . We
also have shown that when LDL is prevented from
peroxidation by AsA, it maintains the same degree of
cholesterol provision to human lymphocytes via the
LDL receptor as does the control LDL of healthy
w xsubjects 17 . These findings suggest that AsA in-
hibits the production of ox-LDL in vivo, and that it
protects against progression toward atherosclerosis.
Epidemiological studies have indicated that a sig-
nificant negative correlation exists between the serum
 .high density lipoprotein HDL cholesterol concentra-
w xtion and development of coronary heart disease 18 .
Experimental findings indicate that HDL has an anti-
w xatherosclerotic action 19 , which is believed to be
derived from its ability to reverse the transport of
cholesterol from peripheral tissues to the liver. In
recent years, however, it has been noted that HDL
also demonstrates an anti-atherosclerotic action by
suppressing the production of ox-LDL through a
w xperoxidation-inhibiting effect 20,21 . It is reported
that HDL inhibits the production of ox-LDL via the
action of paraoxonase, an anti-oxidant enzyme that
w xresides in HDL particles 22 . Also, enzymes such as
 .lecithin–cholesterol acyltransferase LCAT , and
 .platelet activating factor PAF-AH in HDL particle
w xare believed to have anti-oxidative effects 23,24 .
HDL can be divided by density into subfractions of
 . HDL ds1.063 to 1.125 grml and HDL ds2 3
.1.125 to 1.21 grml . HDL are small, lipid-poor3
particles which promote the in vitro efflux of choles-
terol to a greater extent than HDL . HDL are larger,2 2
cholesterol-rich particles that are also rich in apopro-
tein E, which has high ligand activity for hepatic cell
receptors. HDL are thought to be more actively2
w xtaken up by hepatic cells than are HDL 25 . It is3
considered that HDL exerts more powerful anti-3
oxidative effects against LDL oxidation than HDL2
w x21,26 . We have previously reported that although
HDL and HDL both inhibit the Cu2q-induced per-2 3
oxidation of LDL in a dose-dependent manner, this
w xeffect is much more pronounced with HDL 27 .3
Numerous epidemiological studies have shown that
a significant positive correlation exists between the
w xblood levels of AsA and HDL 28,29 . Both sub-
stances are believed to have anti-atherosclerotic ac-
tion, and the two are thought to interact in vivo. In
the present study, we performed in vitro assays to
investigate the effects of coincubation of HDL and3




The pooled sera from 12 healthy normolipidemic
volunteers was treated with NaBr solution containing
30 mM EDTA–2Na prepared by the method of Hatch
w xand Lees 30 to adjust the specific gravity, and LDL
 . ds1.019 to 1.063 grml and HDL ds1.125 to3
. w x1.21 grml were isolated by ultracentrifugation 31 .
Thereafter, lipoproteins were dialyzed at 48C for 24 h
with phosphate-buffered saline solution PBS, 10 mM
sodium phosphate buffer, pH 7.4, containing 150 mM
.NaCl .
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2.2. Protein assays
The total proteins in various lipoprotein fractions
were measured using a micro BCA Kit Pierce, Rock-
.ford, IL, USA and bovine serum albumin as a
w xstandard 32 . The amount of lipoprotein was ex-
pressed in micrograms protein per milliliter mg
.proteinrml .
2.3. LDL peroxidation by copper ion
 .For the preparation of LDL: 1 as the control
LDL, 200 mgrml LDL in PBS solution was mixed
with 0.1 mM EDTA–2Na, to prevent autoxidation
w x33–35 . To obtain ox-LDL and peroxidized HDL3
 .  .  .ox-HDL , 2 200 mgrml LDL in PBS, and 33
200 mgrml HDL in PBS, were mixed with 2.5 mM3
CuSO and incubated for 6 to 24 h. For the test4
 .samples: 4 200 mgrml LDL and 20 mgrml AsA in
 .PBS, 5 200 mgrml LDL and 200 mgrml HDL in3
 .PBS, and 6 200 mgrml LDL, 20 mgrml AsA and
200 mgrml HDL in PBS, were incubated with 2.53
 .  .mM CuSO for 6 to 24 h as in 2 and 3 above.4
LDL peroxidation was stopped by adding 0.1 mM
EDTA–2Na, the chelating agent against copper ion,
to each sample and storing in a refrigerator at 48C
w x  .33 . The prepared samples were then labeled 4
 .  .ox-LDLqAsA, 5 ox-LDLqHDL , and 6 ox-3
LDLqAsAqHDL . It was confirmed in prelimi-3
nary experiments that the conditions mentioned above
are ideal for observation of HDL and AsA interac-3
tions.
2.4. LDL electrophoresis
After peroxidation for 6, 12, 18, and 24 h, the
samples were exhaustively dialyzed against PBS with
0.1 mM EDTA–2Na to remove Cu2q for 24 h.
Thereafter, agarose gel electrophoresis was per-
formed using the Pol-E-Film System to observe LDL
mobility. Electrophoresis was conducted for 50 min
 .at 100 V in 0.05 M barbital buffer pH 8.6 using
Universal Gel as the electrophoretic gel. Gels were
stained with Fat Red 7B, and electrophoretic mobility
 .Fig. 1. Effects of coincubation of high density lipoprotein 3 HDL and AsA on LDL peroxidation. LDL protein, 200 mgrml, from3
 .healthy volunteers was incubated for up to 24 h in PBS containing 2.5 mM CuSO in the absence ox-LDL: ’ or presence of AsA 204
 .  .mgrml ox-LDLqAsA: I , or with HDL protein 200 mgrml ox-LDLqHDL : B , or with HDL protein 200 mgrml and AsA 203 3 3
 .mgrml in combination ox-LDLqAsAqHDL : ‘ . The samples were analyzed at various time points during incubation. The extent of3
 .LDL oxidation is expressed as the ratio of the oxidized LDL relative to the mobility of the control LDL REM on agarose gel
electrophoresis. The REM was determined at the indicated time points, as described in the Section 2. Each point represents the mean of
eight experiments. Significantly lower than the respective ox-LDL values: †p-0.05, ††p-0.01. Significantly lower than the respective
ox-LDLqHDL value: )) p-0.01. Significantly lower than the respective ox-LDLqAsA value: ‡ p-0.01.3
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was measured using a densitometer wavelength: 525
.nm . The extent of LDL peroxidation was expressed
as the ratio of the mobility of the ox-LDL relative to
the mobility of control LDL relative electrophoretic
.mobility: REM .
( )2.5. Assays for lipid hydroperoxide LPO
Samples were dialyzed against PBS containing 0.1
mM EDTA–2Na to remove Cu2q. Thereafter, the
amount of LPO in each sample was measured using a
Determiner LPO kit according to the methylene blue
w xhemoglobin method of Ohishi et al. 36 . The assay is
based on the reaction of LPO with a derivative of
methylene blue in the presence of hemoglobin,
whereby free methylene blue is produced. The amount
of free methylene blue generated from peroxides
were measured with a Hitachi 100-50 spectrophotom-
 .eter Hitachi, Tokyo, Japan , at 675 nm. Measure-
ments were performed in duplicate. The amount of
LPO was expressed in nanomoles per milliliter
 .nmolrml of solution.
2.6. Ascorbic acid assay
The AsA concentrations in ox-LDLqAsA and
ox-LDLqAsAqHDL samples were measured us-3
w xing the 2,4-dinitrophenyl-hydrazine method 37 . The
concentration of AsA was expressed as micrograms
 .per milliliter mgrml
2.7. Statistical analysis
The Wilcoxon signed-rank test was used for statis-
tical analysis, and the significance level was set at
p-0.05.
3. Results
3.1. Agarose gel electrophoresis
The change in REM of each sample incubated for
6, 12, 18, and 24 h is shown in Fig. 1. The REM
value of the ox-LDL sample was 3.16"0.58 mean
Fig. 2. Generation of LPO in LDL incubated with Cu2q in the presence of AsA, HDL , or both AsA and HDL . LDL protein, 2003 3
 .mgrml, from healthy volunteers was incubated for up to 24 h in PBS containing 2.5 mM CuSO in the absence ox-LDL: ’ or presence4
 .  .of AsA 20 mgrml ox-LDLqAsA: I , or with HDL protein 200 mgrml alone ox-LDLqHDL : B , or HDL protein 200 mgrml3 3 3
 .and AsA 20 mgrml in combination ox-LDLqAsAqHDL : ‘ . LPO levels were determined at the indicated time points as described3
 .in the Section 2. The data presented are mean"SE values ns8 . Significantly lower than the respective ox-LDL value: ) p-0.05,
)) p-0.01. Significantly lower than the respective ox-LDLqHDL value: ‡‡ p-0.01. Significantly lower than the respective3
ox-LDLqAsA value: †p-0.05, ††p-0.01.
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."SE, ns8 at 6 h, increased with the time course,
 .and reached a plateau at 12 h 3.61"0.29 . The
REM value of the ox-LDLqHDL sample was 2.213
"0.58 at 6 h, and similarly increased to 3.62"0.20
at 24 h, but was always significantly lower than those
of the ox-LDL value p-0.05, p-0.01, p-0.05,
.p-0.05, respectively, at 6, 12, 18, 24 h . The REM
values of the ox-LDLqAsA and the ox-LDLqAsA
qHDL samples both increased slightly compared3
to the control LDL from respective values of 1.25"
0.13 and 1.15"0.11 at 6 h to 1.45"0.31 and
1.22"0.06 at 12 h. Although the REM value of the
ox-LDLqAsA sample increased to 2.83"0.42 at
18 h, that of the ox-LDLqAsAqHDL sample was3
1.56"0.55, and significantly lower than that of the
 .ox-LDLqAsA sample p-0.01 . The results at 24
h showed that in all cases the REM values for the
 .ox-LDLqHDL 3.13"0.18 , the ox-LDLqAsA3
 . 3.02"0.34 , and the ox-LDLqAsAqHDL 2.023
."0.35 samples were significantly lower than the
REM values of the ox-LDL 3.86"0.11; p-0.05,
.p-0.05, p-0.01, respectively . At 24 h, the REM
values of the ox-LDLqHDL and the ox-LDLq3
AsA samples did not differ significantly. The REM
values of the ox-LDLqAsAqHDL samples were3
significantly lower than the respective values for
ox-LDLqHDL at all time points p-0.01, respec-3
.tively and also significantly lower than values for
the ox-LDLqAsA samples at 18 h and 24 h p-
.0.01, p-0.01, respectively . All data are presented
 .as mean"SE Fig. 1 .
3.2. LPO production
As seen in Fig. 2, the production of LPO in the
ox-LDL samples was highest 274.0"20.3 nmolrml;
.mean"SE, ns8 at the 6 h incubation time and
decreased thereafter. In contrast, the LPO level in the
ox-LDLqHDL sample was 137.1"20.4 nmolrml3
at 6 h, increased to 179.7"20.2 nmolrml at 12 h,
 .peaked at 18 h 189.2"12.4 nmolrml , and de-
creased thereafter. The LPO production in the ox-
LDLqAsA and the ox-LDLqAsAqHDL sam-3
ples at 6 h was below the measurable range. The LPO
level in the ox-LDLqAsA sample gradually in-
creased to 12.2"7.5 nmolrml at 12 h, 108.9"17.2
nmolrml at 18 h, and 139.8"13.0 nmolrml at 24 h.
Although the LPO level in the ox-LDLqAsAq
Fig. 3. Effects of HDL on the concentration of AsA in the medium during LDL peroxidation. LDL protein, 200 mgrml, from healthy3
 .volunteers was incubated in PBS containing 2.5 mM CuSO in the presence of either 20 mgrml AsA ox-LDLqAsA: I or both 204
 .mgrml AsA and 200 mgrml HDL ox-LDLqAsAqHDL : square filled with dots for 24 h. The AsA concentrations in the samples3 3
were determined at the indicated time points using 2,4-dinitrophenyl-hydrazine method. The data presented are mean"SE values
 .ns8 . Significantly higher than the respective ox-LDLqAsA value: )) p-0.001. n.s.: Not significant.
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HDL sample also gradually increased after 6 h, the3
 . values at 12 h 1.5"0.3 nmolrml , 18 h 46.0"21.4
.nmolrml revealed a tendency of lower values than
those respective values for the ox-LDLqAsA at
corresponding times. However, at 24 h, the LPO
 .level 52.9"28.5 nmolrml was significantly lower
than that in the ox-LDLqAsA sample 139.8"13.0
.nmolrml; p-0.05 . The LPO production in the
ox-HDL sample was below the measurable range3
 .throughout the 24 h experimental period Fig. 2 .
3.3. AsA concentration
As seen in Fig. 3, the AsA concentration in the
ox-LDLqAsAqHDL sample after 6 h incubation3
 .13.2"0.4 mgrml; mean"SE, ns8 was signifi-
cantly higher than that in the ox-LDLqAsA sample
 .10.2"0.3 mgrml; p-0.001 , and at 12 h of incu-
bation, the AsA in the ox-LDLqAsAqHDL sam-3
 .ple 6.0"0.4 mgrml was also significantly higher
than that in the ox-LDL sample 4.8"0.5 mgrml;
.p-0.001 . At 18 and 24 h of incubation, values of
both cases were low, and there was no significant
 .difference between both cases Fig. 3 .
4. Discussion
When Cu2q and LDL are coincubated, the Cu2q
binds to a specific site on the apolipoprotein B apo
.B of the LDL and lipid radicals are produced in
w xchain reaction 38–40 . Peroxidation of fatty-acyl
groups proceeds via the formation of a diene conju-
gate and results in a formation of a peroxy radical.
The peroxy radical then either forms a metastable
LPO or breaks down to release a wide variety of
w xaldehydes, ketones, and hydroxylipids 41 . Malondi-
 .  .aldehyde MDA and 4-hydroxynonenal 4-HNE are
thought to increase the negative charge of apo B by
binding to the epsilon amino groups of lysine residues
w xof apo B 34,42 .
The water-soluble vitamin AsA has as an impor-
tant physiological function as an anti-oxidant by pre-
venting initiation and propagation of the free radical
w xchain reaction of lipid peroxidation 17,43 . Further-
more, AsA may exert a direct effect on the break-
w xdown of LDL LPO 44 and preserve lipid soluble
anti-oxidants such as b-carotene and tocopherol in
w xLDL particles 45 . It also has been reported that AsA
has an effect of reducing the tocopheroxyl radical to
w xtocopherol 46 . In the present study, the apparent
mechanism by which AsA suppresses LDL peroxida-
tion is that AsA captures lipid radicals produced
during the coincubation of LDL with Cu2q, thereby
disrupting the chain reaction and preventing the de-
composition of polyunsaturated fatty acids so as to
w xsuppress the modification of apo B 16,17 . AsA is
 .peroxidized to form dehydro-L-ascorbic acid DHA ,
which is believed to prevent the initiation of lipid-
peroxidation of LDL by preventing Cu2q from bind-
ing to LDL particles, thereby inhibiting the produc-
w xtion of ox-LDL 47 . Although the mechanism by
which HDL inhibits peroxidation remains unclear,
many enzymes such as paraoxonase, LCAT, PAF-AH
which reside in HDL particles are believed to possess
this inhibitory effect. Reports indicate that HDL per-
forms as an anti-oxidant during the peroxidation of
w xLDL through the action of these enzymes 23,24,48 .
It has also been reported that HDL suppresses the
production of lipid peroxides via its role as a scav-
w xenger of superoxide anions 49 .
In this study, the consumption of AsA in the
ox-LDLqAsAqHDL samples was suppressed by3
the presence of HDL . The peroxidation of LDL was3
presumably more strongly inhibited in the ox-LDLq
AsAqHDL samples than in the ox-LDLqAsA3
samples through the retention of AsA. Authors pre-
dict that, instead of AsA, HDL may capture lipid3
radicals in LDL, and superoxide anions released from
LDL particles into the PBS medium when LDL is
w xperoxidized 50 . It appears likely that AsA is re-
tained due to substitutive effect of HDL for AsA. It3
is supposed that not only did HDL function as an3
anti-oxidant during the peroxidation of LDL, but it
also enhanced the oxidation-inhibiting effect of AsA
against LDL peroxidation by suppressing its decom-
position, and as a result, the peroxidation of LDL was
vigorously suppressed when HDL and AsA were3
both present.
In our system, although it may be that Cu2q binds
to HDL , thus reducing the Cu2q available to bind3
with LDL, and suppressing the Cu2q-induced produc-
tion of peroxides from LDL, it seems unlikely that
Cu2q binds directly with HDL since the amount of3
LPO was below the measurable range when HDL3
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2q w xwas coincubated with Cu . Mackness et al. 51
have also reported that Cu2q does not bind to HDL.
AsA has been reported to function as a prooxidant
in the presence of transition metals such as Cu2q
w x52 . In the present study, however, AsA functioned
as an anti-oxidant and inhibited the production of
ox-LDL in the presence of Cu2q. The present authors
and others have also reported that a significant posi-
tive correlation exists between the AsA concentra-
tions and HDL cholesterol levels in humans
w x28,29,53 . We suggest that, on the basis of the
present in vitro findings, HDL also suppresses AsA
decomposition and enhances its anti-oxidant action in
vivo.
5. Conclusion
We conclude that the coincubation of HDL and3
AsA exerts more powerful anti-peroxidative effects
against copper-catalyzed per-oxidation, as compared
with presence of either of these agents alone. This
finding suggests that the coincubation of AsA and
HDL may work in vivo to inhibit LDL peroxidation3
to produce a greater anti-atherosclerotic effect.
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